Astellas Rejigs R&D Focus Areas As It Withdraws From Mitochondria R&D
Ex-Mitobridge Asset Dropped
Executive Summary
As Astellas pivots through several candidates in an attempt to create its next blockbuster, a decision to terminate its only prospect in the core mitochondrial R&D area leaves very few other competitors in the market.